Cargando…

Risk of hepatic and extrahepatic cancer in NAFLD: A population‐based cohort study

BACKGROUND AND AIMS: Individuals with non‐alcoholic fatty liver disease (NAFLD) may be at greater risk of cancer. This study aimed to investigate the risk of hepatic and extrahepatic cancer compared to the general population in a population‐based cohort of patients with NAFLD. METHODS: We used the S...

Descripción completa

Detalles Bibliográficos
Autores principales: Björkström, Karl, Widman, Linnea, Hagström, Hannes
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9306866/
https://www.ncbi.nlm.nih.gov/pubmed/35152526
http://dx.doi.org/10.1111/liv.15195
_version_ 1784752636980887552
author Björkström, Karl
Widman, Linnea
Hagström, Hannes
author_facet Björkström, Karl
Widman, Linnea
Hagström, Hannes
author_sort Björkström, Karl
collection PubMed
description BACKGROUND AND AIMS: Individuals with non‐alcoholic fatty liver disease (NAFLD) may be at greater risk of cancer. This study aimed to investigate the risk of hepatic and extrahepatic cancer compared to the general population in a population‐based cohort of patients with NAFLD. METHODS: We used the Swedish National Patient Registry from 1987 to 2016 to identify patients with a NAFLD diagnosis and no prior cancer. All patients with NAFLD were compared to up to 10 controls matched for age, sex and living location. The primary outcome was the first occurrence of any cancer as ascertained from national registries. As secondary outcomes, we analysed the risk of pre‐specified cancer subtypes. Cox regression models, adjusted for baseline diabetes, hypertension, hyperlipidaemia and chronic obstructive pulmonary disease were applied. RESULTS: We identified 8415 patients with NAFLD. Over a median follow‐up of 6.0 years (IQR 2.5–11.2 years), an increased risk for any cancer was found in patients with NAFLD compared to controls (9.7 vs. 8.6 cases per 1000 person‐years): hazard ratio (HR) = 1.22 (95% confidence interval, CI = 1.12–1.33). The risk for hepatocellular carcinoma (HCC) was particularly high (adjusted HR, aHR = 12.18, 95% CI = 7.15–20.79). The risk for some other cancer subtypes increased (colorectal [aHR 1.38], kidney [aHR 2.12], bladder [aHR 2.51] and uterine [aHR 1.78]), but was low in absolute terms. CONCLUSION: In this population‐based cohort, NAFLD was associated with an increased risk of developing cancer (especially HCC). The absolute risk for other forms of cancer was generally comparable to the control population.
format Online
Article
Text
id pubmed-9306866
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-93068662022-07-28 Risk of hepatic and extrahepatic cancer in NAFLD: A population‐based cohort study Björkström, Karl Widman, Linnea Hagström, Hannes Liver Int Metabolic & Toxic Liver Diseases BACKGROUND AND AIMS: Individuals with non‐alcoholic fatty liver disease (NAFLD) may be at greater risk of cancer. This study aimed to investigate the risk of hepatic and extrahepatic cancer compared to the general population in a population‐based cohort of patients with NAFLD. METHODS: We used the Swedish National Patient Registry from 1987 to 2016 to identify patients with a NAFLD diagnosis and no prior cancer. All patients with NAFLD were compared to up to 10 controls matched for age, sex and living location. The primary outcome was the first occurrence of any cancer as ascertained from national registries. As secondary outcomes, we analysed the risk of pre‐specified cancer subtypes. Cox regression models, adjusted for baseline diabetes, hypertension, hyperlipidaemia and chronic obstructive pulmonary disease were applied. RESULTS: We identified 8415 patients with NAFLD. Over a median follow‐up of 6.0 years (IQR 2.5–11.2 years), an increased risk for any cancer was found in patients with NAFLD compared to controls (9.7 vs. 8.6 cases per 1000 person‐years): hazard ratio (HR) = 1.22 (95% confidence interval, CI = 1.12–1.33). The risk for hepatocellular carcinoma (HCC) was particularly high (adjusted HR, aHR = 12.18, 95% CI = 7.15–20.79). The risk for some other cancer subtypes increased (colorectal [aHR 1.38], kidney [aHR 2.12], bladder [aHR 2.51] and uterine [aHR 1.78]), but was low in absolute terms. CONCLUSION: In this population‐based cohort, NAFLD was associated with an increased risk of developing cancer (especially HCC). The absolute risk for other forms of cancer was generally comparable to the control population. John Wiley and Sons Inc. 2022-02-24 2022-04 /pmc/articles/PMC9306866/ /pubmed/35152526 http://dx.doi.org/10.1111/liv.15195 Text en © 2022 The Authors. Liver International published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Metabolic & Toxic Liver Diseases
Björkström, Karl
Widman, Linnea
Hagström, Hannes
Risk of hepatic and extrahepatic cancer in NAFLD: A population‐based cohort study
title Risk of hepatic and extrahepatic cancer in NAFLD: A population‐based cohort study
title_full Risk of hepatic and extrahepatic cancer in NAFLD: A population‐based cohort study
title_fullStr Risk of hepatic and extrahepatic cancer in NAFLD: A population‐based cohort study
title_full_unstemmed Risk of hepatic and extrahepatic cancer in NAFLD: A population‐based cohort study
title_short Risk of hepatic and extrahepatic cancer in NAFLD: A population‐based cohort study
title_sort risk of hepatic and extrahepatic cancer in nafld: a population‐based cohort study
topic Metabolic & Toxic Liver Diseases
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9306866/
https://www.ncbi.nlm.nih.gov/pubmed/35152526
http://dx.doi.org/10.1111/liv.15195
work_keys_str_mv AT bjorkstromkarl riskofhepaticandextrahepaticcancerinnafldapopulationbasedcohortstudy
AT widmanlinnea riskofhepaticandextrahepaticcancerinnafldapopulationbasedcohortstudy
AT hagstromhannes riskofhepaticandextrahepaticcancerinnafldapopulationbasedcohortstudy